You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 SBRT fractionations for NSCLC with clinical outcome and calculated TCP for the 20% hypoxic tumour (Figure 1 i)

From: Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability

Reference Dose scheme Total dose (Gy) Dose prescr. Treatment outcome TCP for LQ (USC)
  Overall survival Local control No LOC LOC
Hof et al. 2007[3] (Germany) 26 Gy × 1 26 Isocenter 74.5% at 1 yeara, 65.4% at 2 yearsa, 37.4% at 3 yearsa 100% at 1 yearb, 72% at ≥ 2 yearsb 0% (0%) N/A
Fritz et al. 2008[4] (Germany) 30 Gy × 1 30 Isocenter 66% at 2 years, 53% at 3 years 81% at 3 years 0% (0%) N/A
Zimmermann et al. 2005[5](Germany 65% isodose) 12.5 Gy × 3 37.5 60% 80% at 1 yearc, 75% at 2 yearsc 100% at 1 yearc, 87% at 2 yearsc 7% (4%) 99% (98%)
Baumann et al. 2009[6] (Sweden) 15 Gy × 3 45 67% 86% at 1 year, 65% at 2 years, 60% at 3 years 92% at 3 years 56% (44%) 100% (99%)
Olsen et al. 2011[7] (USA, The Netherlands) 18 Gy × 3 54 80% 92/81% at 1 yeard, 85/61% at 2 yearsd 99% at 1 yeard, 91% at 2 yearsd 62% (50%) 100% (100%)
Haasbeek et al. 2010[8] (The Netherlands) 20 Gy × 3 60 80% 85.7% at 1 yeare, 54% at 2 yearse, 45.1% at 3 yearse 89% at 3 yearse 96% (92%) 100% (100%)
Takeda et al. 2009[9] (Canada) 10 Gy × 5 50 80% 90/63% at 3 years, (Stage 1A/1B) 93/96% at 3 years, (Stage 1A/1B) 0% (0%) 98% (98%)
Haasbeek et al. 2010[8] (The Netherlands) 12 Gy × 5 60 80% 85.7% at 1 yeare, 54% at 2 yearse, 45.1% at 3 yearse 89% at 3 yearse 29% (28%) 100% (100%)
Haasbeek et al. 2010[8] (The Netherlands) 7.5 Gy × 8 60 80% 85.7% at 1 yeare, 54% at 2 yearse, 45.1% at 3 yearse 89% at 3 yearse 0% (0%) 100% (100%)
  1. aBased on doses 19–30 Gy to isocenter: 19 Gy (1 patient), 22 Gy (2), 24 Gy (7), 26 Gy (14), 28 Gy (10), 30 Gy (30).
  2. bPatients receiving 26–30 Gy.
  3. cDose range 24–40 Gy, 69% was given 37.5 Gy, (2 patients had doses prescribed to 80% isodose).
  4. dDoses prescribed to 60-90% isodose (median 84%), overall survival expressed as operable/inoperable patients and including other dose schemes.
  5. eBased on 60 Gy total doses given in 3, 5 and 8 fractions: 3 × 20 Gy (33%), 5 × 12 Gy (50%), 8 × 7.5 Gy (17%).
  6. N/A = Not Applicable.